Financière de Tubize SA Empfehlungs-Mittelwert
Was ist das Empfehlungs-Mittelwert von Financière de Tubize SA?
Empfehlungs-Mittelwert von Financière de Tubize SA ist 1.00
Was ist die Definition von Empfehlungs-Mittelwert?
Der empfohlene Mittelwert ist der Durchschnitt der Analystenbewertungen der Aktie von 1,0 (starker Kauf) bis 5,0 (starker Verkauf).
Mean of recommendations is an average of ratings from different analysts but it should still be used with other research and investment metrics in order to make investment decisions. It is important to understand a firm's entire scale when assimilating ratings. Additionally, analyst recommendations on stocks owned by firms employing them may be seen as potentially biased.
Financial analysts are often employed by mutual and pension funds, hedge funds, securities firms, banks, investment banks, insurance companies, and other businesses, helping these companies or their clients make investment decisions. Financial analysts employed in commercial lending perform "balance sheet analysis," examining the audited financial statements and corollary data in order to assess lending risks. In a stock brokerage house or in an investment bank, they read company financial statements and analyze commodity prices, sales, costs, expenses, and tax rates in order to determine a company's value and project future earnings. In any of these various institutions, the analyst often meets with company officials to gain a better insight into a company's prospects and to determine the company's managerial effectiveness.
Usually, financial analysts study an entire industry, assessing current trends in business practices, products, and industry competition. They must keep abreast of new regulations or policies that may affect the industry, as well as monitor the economy to determine its effect on earnings.
Empfehlungs-Mittelwert von Unternehmen in Health Care Sektor auf EURONEXT im Vergleich zu Financière de Tubize SA
Was macht Financière de Tubize SA?
Financière de Tubize S.A., through its interest in UCB, operates as a biopharmaceutical company worldwide. It discovers and develops medicines and solutions in the therapeutic areas of neurology and immunology diseases. The company's principal products include Cimzia for treating ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Briviact, Vimpat, and Keppra for the treatment of epilepsy partial-onset seizures; Nayzilam, a nasal spray; and Neupro for treating Parkinson's disease and restless legs syndrome. It also offers Zyrtec and Xyzal for the treatment of allergy; Nootropil for the treatment of psycho-organic syndromes or cognitive decline and cortical myoclonus; and Xyrem for use in treating narcolepsy with cataplexy in adult patients. The company's products in pipeline include padsevonil for drug resistant epilepsy; UCB0107 for treating progressive supranuclear palsy; UCB0599 for Parkinson's disease; UCB7858 for auto-inflammatory diseases; bimekizumab to treat psoriasis, psoriatic arthritis, hidradenitis suppurativa, and axial spondyloarthritis; rozanolixizumab to treat myasthenia gravis, immune thrombocytopenia, and chronic inflammatory demyelinating polyneuropathy; and dapirolizumab pegol for systemic lupus erythematosus. Financière de Tubize S.A. is based in Brussels, Belgium.
Unternehmen mit empfehlungs-mittelwert ähnlich Financière de Tubize SA
- Financière de Tubize SA hat Empfehlungs-Mittelwert von 1.00
- JOYY Inc hat Empfehlungs-Mittelwert von 1.05
- Honda Motor hat Empfehlungs-Mittelwert von 1.06
- Ares Capital Corp hat Empfehlungs-Mittelwert von 1.07
- Petroleo Brasileiro S.A. Petrobras hat Empfehlungs-Mittelwert von 1.08
- VNET Inc hat Empfehlungs-Mittelwert von 1.08
- Rocket Pharmaceuticals Inc hat Empfehlungs-Mittelwert von 1.08